アスピリン薬の2030年までの市場予測：製品別、剤形別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、世界のアスピリン薬市場は2023年に25億米ドルを占め、予測期間中のCAGRは5.4％で成長し、2030年には36億米ドルに達すると予想されています。

アスピリン薬市場には、鎮痛、抗炎症、解熱作用があり、広く使用されている薬であるアセチルサリチル酸、一般的にアスピリンとして知られているを含む医薬品が含まれます。アスピリンは非ステロイド性抗炎症薬（NSAIDs）の一種に属し、鎮痛、炎症抑制、発熱管理に利用されています。さらに、アスピリンは抗凝固作用が認められており、心臓発作や脳卒中などの心血管系イベントの予防に応用されています。

米国を拠点とする国立公衆衛生機関である疾病対策予防センターの報告によると、米国では成人の4人に1人が医師から関節炎と診断されており、その数はおよそ5,850万人にのぼる。

心臓血管の健康への利点

抗血小板作用を持つアスピリンは、心臓発作や脳卒中などの心血管イベントのリスクを低減する能力で広く認知されています。この薬は血栓の形成を阻害することによって作用し、重篤な心血管系の問題につながる血管の閉塞を防ぐ上で極めて重要な因子です。医師は、心血管疾患の既往歴のある人やリスクの高い人に対して、予防的措置としてアスピリンを処方することが多いです。さらに、心筋梗塞のような急性疾患の治療にも有効であることから、心血管治療におけるアスピリンの重要性がさらに強調されています。予防医療の重要性と心血管系リスクの低減におけるアスピリンの役割に関する認識が高まるにつれ、アスピリンの需要は、その確立された、生命を救う心血管系の健康上の利点によって牽引され続けています。

潜在的な副作用に対する意識の高まり

アスピリンに関連する副作用に関する情報が広く行き渡るにつれて、ヘルスケア専門家も消費者もアスピリンの使用に一層の注意を払うようになっています。潰瘍や出血などの消化管合併症のリスクは、よく知られた懸念事項です。このような意識の高まりにより、医療従事者はより慎重な処方を行うようになり、より好ましい副作用プロファイルを持つ代替薬を考慮するようになった。しかし、患者は潜在的なリスクについてより深く知るようになっており、アスピリンの使用、特に長期使用に対する意欲に影響を及ぼしています。

世界の高齢化

世界的に高齢者の数が増加しており、加齢に関連した健康状態、特に心血管疾患の有病率が高くなっています。心血管系に効果があることで知られるアスピリンは、心臓発作や脳卒中の予防薬として高齢者層に一般的に処方されています。高齢者は血栓性イベントのリスクが高いことが多いため、アスピリンはヘルスケアにおける重要な要素となっています。さらに、高齢になると痛みや炎症に関連した症状にかかりやすくなるため、鎮痛・抗炎症薬としてのアスピリンの需要がさらに高まる。

出血のリスク

アスピリンの抗凝固作用は心血管系イベントの予防に重要であるが、同時に出血性合併症のリスクを高める。この懸念は、外科的処置を受ける患者や出血性疾患の既往がある患者にとって特に関連性が高いです。アスピリンの利点と潜在的な副作用の微妙なバランスは、処方する際にヘルスケア専門家が注意深く考慮する必要があります。しかし、出血事象を恐れるあまり、特にリスクとベネフィットの比率を綿密に評価しなければならない特定の患者集団では、アスピリンの処方をためらうことがあります。

COVID-19の影響：

COVID-19患者における心血管合併症の可能性に対する意識の高まりは、予防的措置としてのアスピリン処方の急増につながっています。アスピリンは抗血小板作用を示すため、重症COVID-19症例に関連する血栓性イベントのリスクを軽減する潜在的な役割がしばしば考慮されています。しかし、ヘルスケアサービスの混乱、患者の優先順位の変化、パンデミック時の処方パターンの変化が、世界的に市場に影響を及ぼしています。

予測期間中、エコトリンセグメントが最大となる見込み

エコトリン部門は、腸溶性アスピリン製剤に注力していることから、予測期間中、アスピリン製剤の世界最大市場シェアを占めました。エコトリンは、腸溶性アスピリン製剤で知られるブランドで、アスピリン使用によく関連する胃腸の副作用の問題に対処しています。さらに、腸溶性コーティングにより、アスピリンは刺激を起こすことなく胃を通過し、吸収が起こる腸で薬を放出します。この革新的技術により、胃潰瘍や出血のリスクが軽減され、長期にわたるアスピリン治療が必要な患者にとって薬剤の忍容性が向上します。

予測期間中、チュアブル錠のCAGRが最も高くなると予想されます。

患者の利便性と服薬アドヒアランスに対する市場動向の高まりに伴い、チュアブル錠は従来の錠剤に代わる、より嗜好性が高く使いやすい選択肢を提供します。この技術革新は、高齢者や小児など、錠剤を飲み込むことが困難な人々にアピールします。チュアブル錠セグメントは、より利用しやすく楽しい投薬体験に対する需要を活用し、患者のコンプライアンス向上に貢献しています。さらに、チュアブル・アスピリン錠の心地よい味は、市販の痛み止めを求める人々にとって好ましい選択肢となっています。

最もシェアの高い地域

心血管系の健康に対する意識の高まり、慢性疾患の急増、高齢化人口の増加により、アジア太平洋地域が予測期間中最大の市場シェアを占めると予想されます。この地域の国々が経済発展や都市化を遂げるにつれて、ライフスタイルが進化し、座りがちな習慣の増加や、健康上の懸念の一因となる食生活の変化につながっています。その他の特典として、心血管系疾患の有病率の増加とアスピリンの予防効果に対する理解の高まりが、この医薬品に対する需要の増加を促進しています。

CAGRが最も高い地域：

欧州は、高齢化が進み、心血管疾患の有病率が高いため、心臓発作や脳卒中の予防薬としてアスピリンの需要が高まっています。この地域ではエビデンスに基づく医療が重視され、強力な規制の枠組みが様々な臨床場面でのアスピリンの継続的な処方と使用を支えています。さらに、欧州のヘルスケアシステムにおいて心臓血管の健康が主要な焦点であり続ける中、費用対効果が高く、広く入手可能な薬剤としてのアスピリンの役割は、心血管疾患の管理と予防に対する同地域のコミットメントと一致し、同地域のアスピリン製剤市場の繁栄に大きく貢献しています。

無料のカスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のアスピリン薬市場：製品別

• エコトリン
• バファリン
• ジェネリックアスピリン
• その他の製品

第6章 世界のアスピリン薬市場：剤形別

• 腸溶錠
• チュアブル錠
• 溶解性または発泡性の錠剤
• その他の剤形

第7章 世界のアスピリン薬市場：流通チャネル別

• 薬局・ドラッグストア
• オンライン小売業者
• 食料品店とスーパーマーケット
• 卸売業者
• その他の流通チャネル

第8章 世界のアスピリン薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Cadila Healthcare Limited
• Alembic Pharmaceuticals Limited
• GlaxoSmithKline Consumer Healthcare Ltd
• Takeda Pharmaceutical Company Limited
• Torrent Pharmaceuticals Ltd
• Abbott Laboratories
• Aspen Pharmacare Holdings Limited
• Dr. Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Novartis International AG
• Pfizer Inc
• Bayer AG
• Roche Holding AG

List of Tables

• Table 1 Global Aspirin Drug Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 4 Global Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 5 Global Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 6 Global Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 7 Global Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 8 Global Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 9 Global Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 10 Global Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 11 Global Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 12 Global Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 13 Global Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 14 Global Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 15 Global Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 16 Global Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 17 Global Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 18 North America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 20 North America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 21 North America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 22 North America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 23 North America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 24 North America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 25 North America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 26 North America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 27 North America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 28 North America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 29 North America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 30 North America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 31 North America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 32 North America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 33 North America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 34 North America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 35 Europe Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 37 Europe Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 38 Europe Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 39 Europe Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 40 Europe Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 41 Europe Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 42 Europe Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 43 Europe Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 44 Europe Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 45 Europe Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 46 Europe Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 47 Europe Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 48 Europe Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 49 Europe Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 50 Europe Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 51 Europe Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 52 Asia Pacific Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 54 Asia Pacific Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 55 Asia Pacific Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 56 Asia Pacific Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 57 Asia Pacific Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 58 Asia Pacific Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 59 Asia Pacific Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 60 Asia Pacific Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 61 Asia Pacific Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 62 Asia Pacific Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 63 Asia Pacific Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 64 Asia Pacific Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 65 Asia Pacific Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 66 Asia Pacific Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 67 Asia Pacific Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 68 Asia Pacific Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 69 South America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 71 South America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 72 South America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 73 South America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 74 South America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 75 South America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 76 South America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 77 South America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 78 South America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 79 South America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 80 South America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 81 South America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 82 South America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 83 South America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 84 South America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 85 South America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
• Table 86 Middle East & Africa Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
• Table 88 Middle East & Africa Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
• Table 89 Middle East & Africa Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
• Table 90 Middle East & Africa Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
• Table 91 Middle East & Africa Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
• Table 92 Middle East & Africa Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 93 Middle East & Africa Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
• Table 94 Middle East & Africa Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
• Table 95 Middle East & Africa Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
• Table 96 Middle East & Africa Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
• Table 97 Middle East & Africa Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 98 Middle East & Africa Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
• Table 99 Middle East & Africa Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
• Table 100 Middle East & Africa Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
• Table 101 Middle East & Africa Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
• Table 102 Middle East & Africa Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

According to Stratistics MRC, the Global Aspirin Drug Market is accounted for $2.5 billion in 2023 and is expected to reach $3.6 billion by 2030 growing at a CAGR of 5.4% during the forecast period. The aspirin drug market encompasses pharmaceutical products containing acetylsalicylic acid, commonly known as aspirin, which is a widely used medication with analgesic, anti-inflammatory, and antipyretic properties. Aspirin belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is utilized for pain relief, reduction of inflammation, and fever management. Additionally, aspirin is recognized for its anticoagulant effects, contributing to its application in preventing cardiovascular events such as heart attacks and strokes.

According to a report shared by the Centers for Disease Control and Prevention, a US-based national public health agency, 1 in 4 adults in the US were suffering from doctor-diagnosed arthritis, which is almost 58.5 million people.

Market Dynamics:

Driver:

Cardiovascular health benefits

Aspirin, with its antiplatelet properties, is widely recognized for its ability to reduce the risk of cardiovascular events, including heart attacks and strokes. The drug works by inhibiting the formation of blood clots, a crucial factor in preventing blockages in blood vessels that can lead to severe cardiovascular issues. Physicians often prescribe aspirin as a preventive measure for individuals with a history of cardiovascular diseases or those at higher risk. Additionally, the drug's efficacy in managing acute conditions, such as myocardial infarction, further underscores its importance in cardiovascular care. As awareness grows regarding the significance of preventive healthcare and the role of aspirin in reducing cardiovascular risks, the demand for aspirin continues to be driven by its well-established and life-saving cardiovascular health benefits.

Restraint:

Growing awareness of potential side effects

As information about the adverse effects associated with aspirin becomes more widely disseminated, both healthcare professionals and consumers exercise increased caution in its usage. The risk of gastrointestinal complications, such as ulcers and bleeding, is a well-documented concern. This heightened awareness has led to more prudent prescribing practices by healthcare providers, who may consider alternative medications with a more favorable side effect profile. However, patients are becoming more informed about the potential risks, impacting their willingness to use aspirin, particularly for long-term applications.

Opportunity:

Global aging population

With an increasing number of elderly individuals worldwide, there is a higher prevalence of age-related health conditions, particularly cardiovascular diseases. Aspirin, known for its cardiovascular benefits, is commonly prescribed to the aging demographic as a preventive measure against heart attacks and strokes. The elderly population often experiences a higher risk of thrombotic events, making aspirin a key component in their healthcare regimen. Additionally, as people age, they may be more susceptible to conditions associated with pain and inflammation, further contributing to the demand for aspirin as an analgesic and anti-inflammatory medication.

Threat:

Risk of bleeding

While aspirin's anticoagulant properties are crucial for preventing cardiovascular events, they concurrently elevate the risk of bleeding complications. This concern is particularly relevant for individuals undergoing surgical procedures or those with pre-existing bleeding disorders. The delicate balance between aspirin's benefits and potential adverse effects requires careful consideration by healthcare professionals when prescribing the drug. However, the fear of bleeding events may lead to hesitancy in prescribing aspirin, especially in certain patient populations where the risk-benefit ratio must be meticulously assessed.

COVID-19 Impact:

The increased awareness of potential cardiovascular complications in COVID-19 patients has led to a surge in aspirin prescriptions as a preventive measure. As aspirin exhibits antiplatelet properties, it is often considered for its potential role in mitigating the risk of thrombotic events associated with severe COVID-19 cases. However, disruptions in healthcare services, shifts in patient priorities, and altered prescribing patterns during the pandemic have influenced the market globally.

The ecotrin segment is expected to be the largest during the forecast period

Ecotrin segment commanded the largest market share of aspirin drug globally over the projected period due to its focus on enteric-coated aspirin formulations. Ecotrin, a brand recognized for its enteric-coated aspirin products, addresses the issue of gastrointestinal side effects commonly associated with aspirin use. Furthermore, the enteric coating enables the aspirin to pass through the stomach without causing irritation, releasing the medication in the intestines where absorption occurs. This innovation reduces the risk of stomach ulcers and bleeding, enhancing the drug's tolerability for patients requiring long-term aspirin therapy.

The chewable tablets segment is expected to have the highest CAGR during the forecast period

With a growing market trend toward patient convenience and adherence, chewable aspirin tablets offer a more palatable and user-friendly alternative to traditional pill forms. This innovation appeals to individuals who may have difficulty swallowing pills, including the elderly and children. The Chewable Tablets segment is capitalizing on the demand for a more accessible and enjoyable medication experience, contributing to increased patient compliance. Furthermore, the pleasant taste of chewable aspirin tablets makes them a favorable choice for individuals seeking over-the-counter pain relief options.

Region with largest share:

Due to the rising awareness of cardiovascular health, a surge in chronic diseases, and an expanding aging population, Asia Pacific region is expected to hold largest market share over the forecast period. As countries in the region undergo economic development and urbanization, lifestyles are evolving, leading to an increase in sedentary habits and dietary changes that contribute to health concerns. Additionally, the growing prevalence of cardiovascular diseases in tandem with an increasing understanding of aspirin's preventive benefits is fostering a higher demand for this medication.

Region with highest CAGR:

Europe is expected to hold profitable growth owing to the region's aging population, coupled with a high prevalence of cardiovascular diseases, has propelled the demand for aspirin as a preventive measure against heart attacks and strokes. The region's emphasis on evidence-based medicine and a strong regulatory framework supports the continued prescription and use of aspirin in various clinical contexts. Additionally, as cardiovascular health remains a primary focus in European healthcare systems, aspirin's role as a cost-effective and widely available medication aligns with the region's commitment to managing and preventing cardiovascular diseases, thereby contributing significantly to the flourishing aspirin drug market in the region.

Key players in the market:

Some of the key players in Aspirin Drug market include Cadila Healthcare Limited, Alembic Pharmaceuticals Limited, GlaxoSmithKline Consumer Healthcare Ltd, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd, Abbott Laboratories, Aspen Pharmacare Holdings Limited, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc, Bayer AG and Roche Holding AG.

Key Developments:

In December 2023, Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co Ltd, has entered into a licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension in six dosage strengths for the United States (US) market, the company in a regulatory filing with the BSE. The terms of the agreement will result in Zydus assuming full responsibility for the clinical development and commercialisation in the US market. Daewoong, on the other hand, will be responsible for the pre-clinical studies, production, and supply of the product.

In March 2023, Ahmedabad-based Cadila Pharmaceuticals has signed a Memorandum of Understanding (MoU) with the government of Gujarat to invest Rs 1,000 crore in different existing projects. The MoU was signed in Gandhinagar between Industries Commissioner Rahul Gupta on behalf of the government of Gujarat and Cadila Pharmaceuticals COO, Mitul Dave, under the Government of Gujarat's "Atma Nirbhar Gujarat Schemes for Assistance to Industries".

Products Covered:

• Ecotrin
• Bufferin
• Generic Aspirin
• Other Products

Dosage Forms Covered:

• Enteric-Coated Tablets
• Chewable Tablets
• Dissolvable or Effervescent Tablets
• Other Dosage Forms

Distribution Channels Covered:

• Pharmacies and Drugstores
• Online Retailers
• Grocery Stores and Supermarkets
• Wholesale Distributors
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Aspirin Drug Market, By Product

• 5.1 Introduction
• 5.2 Ecotrin
• 5.3 Bufferin
• 5.4 Generic Aspirin
• 5.5 Other Products

6 Global Aspirin Drug Market, By Dosage Form

• 6.1 Introduction
• 6.2 Enteric-Coated Tablets
• 6.3 Chewable Tablets
• 6.4 Dissolvable or Effervescent Tablets
• 6.5 Other Dosage Forms

7 Global Aspirin Drug Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Pharmacies and Drugstores
• 7.3 Online Retailers
• 7.4 Grocery Stores and Supermarkets
• 7.5 Wholesale Distributors
• 7.6 Other Distribution Channels

8 Global Aspirin Drug Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Cadila Healthcare Limited
• 10.2 Alembic Pharmaceuticals Limited
• 10.3 GlaxoSmithKline Consumer Healthcare Ltd
• 10.4 Takeda Pharmaceutical Company Limited
• 10.5 Torrent Pharmaceuticals Ltd
• 10.6 Abbott Laboratories
• 10.7 Aspen Pharmacare Holdings Limited
• 10.8 Dr. Reddy's Laboratories Ltd
• 10.9 Sun Pharmaceutical Industries Ltd
• 10.10 Teva Pharmaceutical Industries Ltd
• 10.11 Novartis International AG
• 10.12 Pfizer Inc
• 10.13 Bayer AG
• 10.14 Roche Holding AG